title: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
abstract: The majority of patients with chronic myeloid leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or lose their initial response. In 2006, the European LeukemiaNet published recommendations designed to help identify patients responding poorly to imatinib. Patients were evaluated at 3, 6, 12, and 18 months and some were classified as "failure" or "suboptimal responders." We analyzed outcomes for 224 patients with chronic myeloid leukemia in chronic phase treated in a single institution to validate these recommendations. Patients were followed for a median of 46.1 months. At each time point, patients classified as "failure" showed significantly worse survival, progression-free survival, and cytogenetic response than other patients; for example, based on the assessment at 12 months, the 5-year survival was 87.1% versus 95.1% (P = .02), progression-free survival 76.% versus 90% (P = .002), and complete cytogenetic response rate 26.7% versus 94.1% (P < .001). Similarly, the criteria for "suboptimal response" at 6 and 12 months identified patients destined to fare badly, although criteria at 18 months were less useful. The predictive value of some other individual criteria varied. In general, the LeukemiaNet criteria have useful predictive value, but a case could now be made for combining the categories "failure" and "suboptimal response."
authors: Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom. d.marin@imperial.ac.uk
authors: David
authors: D
authors: Marin
authors: Dragana
authors: D
authors: Milojkovic
authors: Eduardo
authors: E
authors: Olavarria
authors: Jamshid S
authors: JS
authors: Khorashad
authors: Hugues
authors: H
authors: de Lavallade
authors: Alistair G
authors: AG
authors: Reid
authors: Letizia
authors: L
authors: Foroni
authors: Katayoun
authors: K
authors: Rezvani
authors: Marco
authors: M
authors: Bua
authors: Francesco
authors: F
authors: Dazzi
authors: Jiri
authors: J
authors: Pavlu
authors: Matthias
authors: M
authors: Klammer
authors: Jaspal S
authors: JS
authors: Kaeda
authors: John M
authors: JM
authors: Goldman
authors: Jane F
authors: JF
authors: Apperley
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D016208:Databases, Factual; D019008:Drug Resistance, Neoplasm; D005060:Europe; D005260:Female; D006287:Health Planning Guidelines; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D016019:Survival Analysis; D017211:Treatment Failure; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate